EA
ANIP icon

Evolution Advisers’s ANI Pharmaceuticals ANIP Stock Holding History

Evolution Advisers’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+3
New +$241 ﹤0.01% 251

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolution Advisers's ANIP Position: Q2 2026 in Review

Evolution Advisers opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 3 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #251 among its holdings.

307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Evolution Advisers held 3 shares of ANI Pharmaceuticals worth $0 as of Q2 2026.
  • ANI Pharmaceuticals was a new Evolution Advisers position in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #251 holding.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.